MENRIUM 10-4

Clinical safety rating: caution

Comprehensive clinical and safety monograph for MENRIUM 10-4 (MENRIUM 10-4).

How it works

Mennium 10-4 is a combination of chlordiazepoxide, a benzodiazepine that enhances GABA-A receptor activity, and clidinium, an antimuscarinic that blocks muscarinic acetylcholine receptors.

What the body does with it

Metabolism	Chlordiazepoxide: Hepatic metabolism via CYP3A4 to active metabolites (desmethylchlordiazepoxide, demoxepam). Clidinium: Hepatic metabolism (primary pathway unclear).
Excretion	Renal (60% as unchanged chlordiazepoxide, 15% as conjugated metabolites; 5% biliary/fecal as metabolites)
Half-life	Chlordiazepoxide: 5-30 h (mean 20 h); clidinium: 10-20 h. Steady-state reached in 5-7 days.
Protein binding	Chlordiazepoxide: 96-98% bound to albumin. Clidinium: ~80% bound.
Volume of Distribution	Chlordiazepoxide: 0.3-0.5 L/kg; clidinium: 1.2-1.7 L/kg. Moderate tissue distribution.
Bioavailability	Oral: 100% (chlordiazepoxide); clidinium: 10-30% (extensive first-pass metabolism).
Onset of Action	Oral: 30-60 min (anxiolytic); 15-30 min (antispasmodic).
Duration of Action	4-6 h (clinical effect); 24-48 h (residual sedation due to active metabolite nordiazepam).

Classification & Brands

Dosing & administration

Adults: 1 tablet (chlordiazepoxide 10 mg / clidinium 4 mg) orally 3 to 4 times daily before meals and at bedtime. Max: 4 tablets per day.

Dosage form	TABLET
Renal impairment	Use with caution in renal impairment. GFR ≥10 mL/min: no adjustment; GFR <10 mL/min: avoid due to risk of accumulation of chlordiazepoxide metabolites. Not recommended in end-stage renal disease.
Liver impairment	Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated due to impaired clearance.
Pediatric use	Not recommended for use in children. Safety and efficacy not established. For patients under 12 years, avoid use.
Geriatric use	Elderly patients are more sensitive to CNS effects. Initial dose: 1 tablet (5 mg chlordiazepoxide / 2.5 mg clidinium) twice daily; titrate slowly. Avoid doses >2 tablets per day. Monitor for sedation and anticholinergic side effects.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for MENRIUM 10-4 (MENRIUM 10-4).

Breastfeeding	Chlordiazepoxide and its metabolites are excreted in breast milk. M/P ratio not established. Potential for infant sedation and withdrawal. Use only if benefit outweighs risk; monitor infant for drowsiness and feeding difficulties.
Teratogenic Risk	First trimester: Increased risk of congenital malformations, particularly cleft palate and neural tube defects, due to chlordiazepoxide. Second and third trimesters: Risk of neonatal withdrawal, respiratory depression, hypotonia, and sedation. Benzodiazepines are associated with floppy infant syndrome and dependence.

Warnings & precautions

■ FDA Black Box Warning

Concomitant use of benzodiazepines with opioids may result in profound sedation, respiratory depression, coma, and death. Reserve for use in patients for whom alternative treatment options are inadequate.

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to chlordiazepoxide, clidinium, or any component","Narrow-angle glaucoma (due to anticholinergic effects)","Obstructive uropathy (e.g., prostatic hypertrophy)","Myasthenia gravis"]

Clinical Precautions

Precautions

["Dependence and withdrawal reactions with prolonged use","Abuse potential","CNS depressant effects; caution with other CNS depressants","Paradoxical reactions (restlessness, agitation)","Elderly patients more sensitive to anticholinergic effects (constipation, urinary retention, blurred vision)","Impaired renal function may require dose adjustment"]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

MENRIUM 10-4

Clinical safety rating: caution

Comprehensive clinical and safety monograph for MENRIUM 10-4 (MENRIUM 10-4).

How it works

Mennium 10-4 is a combination of chlordiazepoxide, a benzodiazepine that enhances GABA-A receptor activity, and clidinium, an antimuscarinic that blocks muscarinic acetylcholine receptors.

What the body does with it

Metabolism	Chlordiazepoxide: Hepatic metabolism via CYP3A4 to active metabolites (desmethylchlordiazepoxide, demoxepam). Clidinium: Hepatic metabolism (primary pathway unclear).
Excretion	Renal (60% as unchanged chlordiazepoxide, 15% as conjugated metabolites; 5% biliary/fecal as metabolites)
Half-life	Chlordiazepoxide: 5-30 h (mean 20 h); clidinium: 10-20 h. Steady-state reached in 5-7 days.
Protein binding	Chlordiazepoxide: 96-98% bound to albumin. Clidinium: ~80% bound.
Volume of Distribution	Chlordiazepoxide: 0.3-0.5 L/kg; clidinium: 1.2-1.7 L/kg. Moderate tissue distribution.
Bioavailability	Oral: 100% (chlordiazepoxide); clidinium: 10-30% (extensive first-pass metabolism).
Onset of Action	Oral: 30-60 min (anxiolytic); 15-30 min (antispasmodic).
Duration of Action	4-6 h (clinical effect); 24-48 h (residual sedation due to active metabolite nordiazepam).

Classification & Brands

Dosing & administration

Adults: 1 tablet (chlordiazepoxide 10 mg / clidinium 4 mg) orally 3 to 4 times daily before meals and at bedtime. Max: 4 tablets per day.

Dosage form	TABLET
Renal impairment	Use with caution in renal impairment. GFR ≥10 mL/min: no adjustment; GFR <10 mL/min: avoid due to risk of accumulation of chlordiazepoxide metabolites. Not recommended in end-stage renal disease.
Liver impairment	Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated due to impaired clearance.
Pediatric use	Not recommended for use in children. Safety and efficacy not established. For patients under 12 years, avoid use.
Geriatric use	Elderly patients are more sensitive to CNS effects. Initial dose: 1 tablet (5 mg chlordiazepoxide / 2.5 mg clidinium) twice daily; titrate slowly. Avoid doses >2 tablets per day. Monitor for sedation and anticholinergic side effects.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for MENRIUM 10-4 (MENRIUM 10-4).

Breastfeeding	Chlordiazepoxide and its metabolites are excreted in breast milk. M/P ratio not established. Potential for infant sedation and withdrawal. Use only if benefit outweighs risk; monitor infant for drowsiness and feeding difficulties.
Teratogenic Risk	First trimester: Increased risk of congenital malformations, particularly cleft palate and neural tube defects, due to chlordiazepoxide. Second and third trimesters: Risk of neonatal withdrawal, respiratory depression, hypotonia, and sedation. Benzodiazepines are associated with floppy infant syndrome and dependence.

Warnings & precautions

■ FDA Black Box Warning

Side Effect Profile

Serious Effects

Absolute Contraindications

["Hypersensitivity to chlordiazepoxide, clidinium, or any component","Narrow-angle glaucoma (due to anticholinergic effects)","Obstructive uropathy (e.g., prostatic hypertrophy)","Myasthenia gravis"]